Ontention of antisera against a hypothalamic decapeptide (luteinizing hormone/follicle stimulating hormone releasing hormone) which stimulates the release of pituitary gonadotropins and development of its radioimmunoassay

Using the classical approach, a decapeptide was synthesized with the structure of porcine luteinizing hormone/follicle stimulating hormone releasing hormone reported by Matsuo, H., Baba, Y., Nair, R. M. G., Arimura, A. and Schally, A. V. (1971) Biochem. Biophys. Res. Commun. 43, 1393–1399. As already reported, this peptide was capable of inducing in vitro the release of luteinizing hormone and follicle stimulating hormone from rat pituitary glands. A specific antiserum against luteinizing hormone/follicle stimulating hormone releasing hormone has been generated in the guinea pig and this allowed the development of a radioimmunoassay for this peptide. The antisera, at a final dilution of to depending on the antiserum used, were able to bind 35% of the ¹³¹I-labelled antigen. The sensitivity of this assay method was 50 pg of luteinizing hormone/follicle stimulating hormone releasing hormone. The following substances did not cross-react: oxytocin, lysine-vasopressin, synthetic thyroid stimulating hormone releasing hormone, ovine luteinizing hormone, follicle stimulating hormone and prolactin. Des-Trp³ luteinizing hormone/follicle stimulating hormone releasing hormone, pyroglutamyl-histidyl-tryptophan and seryl-tyrosyl-glycyl-leucyl-arginyl-prolyl-glycinamide, exhibited flatter curves than luteinizing hormone/follicle stimulating hormone releasing hormone with a cross-reactivity of about . Using this method, luteinizing hormone/follicle stimulating hormone releasing hormone was assayed in extracts of the sheep stalk-median eminence and of the hypothalamus and in jugular vein blood from a normal ram and from normal male rats, from cyclic ewe and from hypophysectomized ram and rats. It was concluded that luteinizing hormone/follicle stimulating hormone releasing hormone is present in hypothalamic extracts and in plasma of sheep and rat.     

Induction of ovarian follicular development in the subadult frogRana tigrina using luteinizing hormone releasing hormone-acetate

In the subadultRana tigrina administration of 2 μg luteinizing hormone releasing hormone-acetate/frog six days a week for 4 weeks in April resulted in the formation of medium (in all 8 frogs) and large sized (in 4 out of 8 frogs) yolky oocytes and, concomitant increases in the oviductal mass. The ovarian and oviductal masses showed a 10-fold increase over the control frogs. In untreated frogs the ovaries were transparent and contained first growth phase oocytes only. The oviducts were also infantile. The pituitary sections were stained using antisera raised in rabbit against the β-subunit of human luteinizing hormone and human follicle stimulating hormone. Immunoreactivity, staining intensity, cytoplasmic granulation and, cell, nuclear and cytoplasmic areas of gonadotrophs (B₂ cells) increased significantly in luteinizing hormone releasing hormone treated frogs. The above findings suggest that pituitary-ovarian axis in the subadultRana tigrina is responsive to luteinizing hormone releasing hormone and that long-term treatment with the hormone induces cytomorphological changes in the gonadotrophs which result in the conversion of inactive cells into secretory cells. This is accompanied by precocious vitellogenic growth of oocytes in the subadult frogs.     

A possible role for copper-mediated oxidation of thiols in the regulation of the release of luteinizing hormone releasing hormone from isolated hypothalamic granules

Abstract: A role for copper in the release of luteinizing hormone releasing hormone (LHRH) from hypothalamic neurons has been previously proposed. To elucidate further the mechanism of action of copper, we addressed two questions: (a) what is the active form of copper that interacts with the LHRH granule (ionic or chelated)? and (b) is copper-stimulated LHRH release a result of an interaction of copper with thiol groups and, if so, does it require oxygen? Granules were isolated from hypothalami of adult male rats and were then incubated at 37°C for 3–5 min in a buffered medium. When granules were incubated with various copper complexes, CuATP stimulated LHRH release by 45 ± 4% (mean ± SE), copper tartrate by 44 ± 4%, CuBSA by 27 ± 7%, and copper histidine by 16 ± 6%. Neither CuEDTA nor CuCl₂ stimulated LHRH release. CuATP-stimulated LHRH release from granules incubated under N₂ was 50% of that incubated under air. Furthermore, the CuATP-stimulated release of LHRH was completely inhibited by dithiothreitol or glutathione (10^?3M each), partially (40–50%) by iodoacetate or 5,5-dithiobis-(2-nitrobenzoic acid), and not at all by oxidized dithiothreitol. Thus, chelated copper, rather than ionic copper, is the active form of the metal, and the action of copper involves an oxidation reaction and granule thiol groups. The precise mechanism of action of copper, however, has yet to be elucidated. We propose that copper may affect LHRH release as follows: copper, bound to an intracellular chelator (protein, peptide, or amino acid), oxidizes thiols of the LHRH granule, leading to a change in granule-membrane permeability and hence to LHRH release.     

Isolation and structural characterization of chicken hypothalamic luteinizing hormone releasing hormone

Studies on partially purified chicken hypothalamic luteinizing hormone releasing hormone (LHRH) utilizing chromatography, radioimmunoassay with region-specific antisera, enzymic inactivation, and chemical modification established that the peptide is structurally different from mammalian hypothalamic LHRH. These studies demonstrated that arginine in position 8 is substituted by a neutral amino acid. On the basis of conformational criteria and evolutionary probability of amino acid interchange for arginine, the most likely substitution was glutamine. We therefore synthesized [Gln8]-LHRH and established that it had identical chromatographic, immunologic, and biological properties to the natural chicken peptide. In concurrent studies, purification of 17 micrograms of an LHRH from 249,000 chicken hypothalami was achieved using acetic acid extraction, immuno-affinity chromatography, and cation exchange and reverse phase high performance liquid chromatography. Amino acid composition and sequence analyses confirmed the structure of this form of chicken LHRH as pGlu-His-Trp-Ser-Tyr-Gly-Leu-Gln-Pro-Gly-NH2.     

The use of bacitracin as an inhibitor of the degradation of thyrotropin releasing factor and luteinizing hormone releasing factor

Bacitracin was found to be an effective inhibitor of the $\text{in}\text{vitro}$ degradation of both thyrotropin releasing factor¹ (TRF) and luteinizing hormone releasing factor (LRF) by guinea pig hypothalamic and whole brain homegenates and rat hypothalamic homogenates and subcellular fractions. Bacitracin was effective in inhibiting the degradation of TRF and LRF, as determined by radioimmunoassay, where it exhibited no interference with the assays. Kinetic studies of the degradation of exogenous synthetic [³H]-TRF demonstrated non-competitive inhibition by bacitracin with K_i = 1.9 × 10^?5 M, while studies on the degradation of [³H] LRF indicated competitive inhibition with K_i = 1.7 × 10^?5 M. Electrophoretic and amino acid analysis revealed that bacitracin itself was not degraded during the course of the $\text{in}\text{vitro}$ incubation.     

An improved synthesis of thyrotropin releasing hormone (TRH) and crystallization of the tartrate

An improved synthesis of thyrotropin releasing hormone (TRH), pGlu-His-Pro-NH₂, is reported. Z-pGlu-ONB (N-hydroxy-5-norbornene-2,3-dicarboximide ester) was reacted with H-His-OH to yield a crystalline Z-pGlu-His-OH which was coupled with H-Pro-NH₂ by the $\text{HONB}\text{DCC}$ method to give Z-pGlu-His-Pro-NH₂ as a fine crystal. Hydrogenation of this protected tripeptide yielded pure TRH nearly quantitatively. The optical purity of TRH thus obtained was confirmed by the method L- and D- amino acid oxidase digestion. The crystallization of TRH was achieved as a tartrate, and the properties of the crystalline TRH-tartrate are described.     

Higher molecular weight immunoreactive species of luteinizing hormone releasing hormone: possible precursors of the hormone.

Separation of extracts of sheep hypothalami on Sephadex G-25 gave three peaks exhibiting luteinizing hormone releasing hormone immunoreactivity. One peak corresponded in elution volume with luteinizing hormone releasing hormone but the others (I and II) eluted earlier, indicating that they are of higher molecular weight. Elution volumes were unaffected by 8 M urea treatment. Incubation of I and II with hypothalamic peptidases produced a small quantity of immunoreactive material eluting in the luteinizing hormone releasing hormone region. Digestion of I with trypsin resulted in a marked increase in total immunoreactivity and the production of material with the same elution volume as II. Tryptic digestion of II gave rise to a small quantity of immunoreactive peptide eluting in the luteinizing hormone releasing hormone region. The amount of I and II relative to luteinizing hormone releasing hormone was lower in the median eminence than in the supra optic chiasmatic and basal hypothalamic regions.     

The participation of corticosterone in luteinizing hormone releasing hormone (LH-RH) action on luteinizing hormone (LH) release from anterior pituitary cells in vitro

Corticosterone alone was not able to stimulate release of luteinizing hormone (LH) from anterior pituitary cells $\text{in}$$\text{vitro}$, but corticosterone in combination with luteinizing hormone releasing hormone (LHRH) augmented the release of LH into the culture media. These results may indicate that corticosterone may have the capacity to activate membrane receptors for LHRH in the gonadotrophs.     

Action of luteinizing hormone-releasing hormone and synthesis of prostaglandin in the pituitary gland

The possibility that prostaglandin E₂ (PGE₂) may play a role in luteinizing hormone (LH) release was examined using an model. Addition of luteinizing hormone-releasing hormone (LH-RH) to the culture medium stimulated cyclic AMP accumulation and LH-release by incubated hemipituitaries, but did not affect the level of PGE₂ or prostaglandin synthetase activity in the gland. Aspirin and indomethacin reduced both prostaglandin synthetase activity and PGE₂ content in the pituitary, but did not impair the stimulatory action of LH-RH on either cyclic AMP accumulation or LH-release. Flufenamic acid on its own caused LH-release, but the drug abolished the effect of LH-RH on cyclic AMP accumulation. The mechanism of this action of flufenamic acid is not understood.It is concluded that the stimulatory action of LH-RH on pituitary cyclic AMP production and LH release is not mediated by prostaglandins.     

5,6-Epoxyeicosatrienoic acid mobilizes Ca2+ in anterior pituitary cells

Luteinizing hormone releasing hormone stimulates the concomitant release of luteinizing hormone and 45Ca2+ from prelabeled anterior pituitary cells. Indomethacin (10 microM) and nordihydroguaiaretic acid (10 microM) had no effect on the luteinizing hormone releasing hormone-stimulated release of either luteinizing hormone or 45Ca2+. Eicosatetraynoic acid (10 microM) blocked both luteinizing hormone releasing hormone-stimulated luteinizing hormone secretion and luteinizing hormone releasing hormone-stimulated 45Ca2+ efflux. 5,6-Epoxyeicosatrienoic acid stimulated both luteinizing hormone secretion and 45Ca2+ efflux from anterior pituitary cells. Additionally, 5,6-epoxyeicosatrienoic acid closely mimics the ability of luteinizing hormone releasing hormone to increase intracellular free calcium. These results are consistent with the hypothesis that 5,6-EET alters calcium homeostasis in a manner similar to that observed during luteinizing hormone releasing hormone stimulation of luteinizing hormone release.     

Hypothalamic-pituitary-adrenal and -gonadal axis function after exercise in sedentary and endurance trained elderly males

The aim of this study was to investigate hypothalamic-pituitary-adrenal (HPAA) and -gonadal (HPGA) axis responses to post-exercise (30 min at 65% V˙O_2max) combined corticotrophin, luteinizing hormone and thyrotrophin releasing hormone challenge (0.7 μg/kg body mass) in elderly distance runners (DR; age: 68.9 ± 4.2 year) and sedentary individuals (SI; age: 69.1 ± 2.6 year). Plasma cortisol, growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone and total testosterone (T) concentrations pre- and post-exercise as well as in response to stimulation did not differ between DR and SI. Plasma adrenocorticotropic hormone returned to pre-exercise level in DR 60 min and in SI 90 min post-stimulation. Free T was lower in DR at all time points. Our results do not support the notion of altered releasing hormone-stimulable HPAA and HPGA synthesis-secretion capacity in elderly males after endurance training. Accepted: 18 November 1997     

Profiling of urinary testosterone and luteinizing hormone in exercise-stressed male athletes,using gas chromatography-mass spectrometry and enzyme immunoassay techniques

Knowledge of the effects of episodic or short-term exercise-stress on endogenous testosterone and luteinizing hormone levels still remains fragmentary and inconclusive. In this study, an approach based on the absolute concentrations of urinary total testosterone (T), luteinizing hormone (LH) and the T/LH concentration ratios, was used to profile short-term exercise-stress responses in healthy drug-free male athletes. Testosterone and luteinizing hormone concentrations were measured using gas chromatography-mass spectrometry (GC-MS) and microparticle enzyme immunoassay (MEIA) techniques, respectively. Stress profiles derived from exercise-stress at VO₂max, 68.1% VO₂max and 51.6% VO₂max were plotted using the concentrations of T, LH and the ratios of T/LH found under non-stressed and stressed conditions. Significant changes in LH concentrations (p<0.005) and T/LH ratios (p<0.005) levels were observed between the pre-stress and post-exercise conditions during acute exercise-stress at VO₂max but the T concentration did not show any marked change relative to the non-stressed condition. Whilst exercise-stress appeared to reduce the change in T concentrations between the pre- and post-exercise states compared to that in the non-stressed control condition, the change in LH concentrations showed a moderate increase at submaximal oxygen uptake values. The stress profiles derived from this study facilitated an assessment of the relationship between the endogenous T, LH and T/LH ratio stress-responses over a short period of applied exercise-stress.     

Isolation and characterization of luteinizing hormone from amphibian (Rana catesbeiana) pituitaries.

We report here the first isolation of an anterior pituitary hormone from an amphibian species, the bullfrog ($\text{Rana catesbeiana}$). Highly purified luteinizing hormone was isolated from alkaline extracts of bullfrog pituitaries by salt fractionation, chromatography on ion-exchangers and gel filtration. Characterization studies show the hormone to contain 9% carbohydrate and to possess an amino acid composition similar to ovine luteinizing hormone. Sedimentation-velocity experiments in the ultracentrifuge indicate that the bullfrog gonadotropin dissociates in acidic solution and is composed of subunits. Bullfrog luteinizing hormone is highly active in an $\text{in vitro}$ toad ovulation assay and also ellicits testosterone production $\text{in vitro}$ from isolated rat testis Leydig cells.     

Demonstration of a macromolecule cross-reacting with antibodies to luteinizing hormone releasing hormone and its tissue distribution

Hypothalamic cytosol contains a macromolecule which cross-reacts with antibodies to luteinizing hormone releasing hormone (LRH). This cross-reacting material (macro-CRM) is insoluble in methanol or acid ethanol, and its molecular weight is about 70,000. Macro-CRM is also found in cytosols of extra-hypothalamic regions of the brain, liver, kidney, spleen, and skeletal muscle. Plasma contains only marginal amounts of macro-CRM. This substance inhibits the binding of [¹²⁵I]LRH to LRH antibodies in a reversible, competitive manner.     

A regulator of G Protein signaling, RGS3, inhibits gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) secretion

Background  

Luteinizing hormone secreted by the anterior pituitary gland regulates gonadal function. Luteinizing hormone secretion is regulated both by alterations in gonadotrope responsiveness to hypothalamic gonadotropin releasing hormone and by alterations in gonadotropin releasing hormone secretion. The mechanisms that determine gonadotrope responsiveness are unknown but may involve regulators of G protein signaling (RGSs). These proteins act by antagonizing or abbreviating interaction of Gα proteins with effectors such as phospholipase Cβ. Previously, we reported that gonadotropin releasing hormone-stimulated second messenger inositol trisphosphate production was inhibited when RGS3 and gonadotropin releasing hormone receptor cDNAs were co-transfected into the COS cell line. Here, we present evidence for RGS3 inhibition of gonadotropin releasing hormone-induced luteinizing hormone secretion from cultured rat pituitary cells.     

Purification,characterisation and amino acid composition of the putative moult-inhibiting hormone (MIH) ofCarcinus maenas (Crustacea,Decapoda)

Summary Using a Y-organ in vitro assay to measure repression of ecdysteroid synthesis in the presence of putative moult-inhibiting hormone (MIH), in conjunction with HPLC separation of sinus gland neuropeptides ofCarcinus maenas, it was found that both the hyperglycemic hormone (CHH) and a novel peptide (argued to represent the MIH) inhibited ecdysteroid synthesis. The latter was purified to homogeneity, and amino acid analysis showed that it is a 61 residue peptide (minimum molecular mass 7,200 Da) with the following amino acid composition: Asx₉; Thr₂; Ser₂; Glx₇; Pro₁; Gly₄; Ala₂; 1/2 Cys₄; Val₄; Met₁; Ile₃; Leu₅; Tyr₁; Phe₃; His₃; Trp₂; Lys₂; Arg₆. The N-terminus appears to be blocked. MIH is at least 20 times more potent than CHH in repressing ecdysteroid synthesis and is active at concentrations of less than 250 pmol/l. There may be structural similarities between CHH and MIH, howeve, MIH displays no CHH radioimmunoreactivity or hyperglycemic activity. The physiological significance of CHH in controlling ecdysteroid titres is not known.Abbreviations CHH hyperglycemic hormone - MIH moult inhibiting hormone - PAGE polyacrylamide gel electrophoresis - RIA radioimmunoassay - SDS sodium dodecyl sulfate - SG smus gland(s) - SGE sinus gland equivalent - TFA trifluoroacetic acid     

Leydig cell receptors for luteinizing hormone releasing hormone and its agonists and their modulation by administration or deprivation of the releasing hormone

Leydig cells isolated from adult rat testes bound ¹²⁵I-labelled luteinizing hormone releasing hormone (LHRH) agonist with high affinity (K_A=1.2 × 10⁹M) and specificity. LHRH and the 3–9 and 4–9 fragments of LHRH agonist competed for binding sites with ¹²⁵I-LHRH agonist but with reduced affinities, whereas fragments of LHRH, and oxytocin and TRH were largely inactive. Somatostatin inhibited binding at high (10^?4M) concentrations but was inactive at 10^?6M and less. Pretreatment of rats for 7 days with 5 μg/day of LHRH agonist reduced binding of ¹²⁵I-LHRH agonist to Leydig cells $\text{in vitro}$ by 25%, whilst inhibition of endogenous LHRH by antibodies for 7 days caused a 40% decrease.     

Effect of indomethacin and 7-oxa-13-prostynoic acid on luteinization of transplanted rat ovarian follicles induced by luteinizing hormone and prostaglandin E2

The ability of prostaglandin E₂ (PGE₂) to initiate luteinization was demonstrated using a system of in vitro incubation of ovarian follicles followed by transplantation. Follicles from diestrous rats were incubated with 0.05 to 50 μg/ml PGE₂, 10 μg/ml luteinizing hormone (LH), or alone in Krebs-Ringer bicarbonate buffer plus glucose for 2 hr. Then follicles were transplanted under the kidney capsules of hypophysectomized recipients, with follicles exposed to PGE₂ on one side and those exposed to LH or buffer only on the other side. As determined at autopsy 4 days later and confirmed by histological examination, follicles exposed to PGE₂ at concentrations of 0.5 μg/ml or greater, or to LH, transformed into corpora lutea, but control follicles regressed. Incubation of follicles with LH in the presence of indomethacin, an inhibitor of prostaglandin synthesis, significantly reduced the incidence of luteinization. Prostaglandin E₂ (10 μg/ml) was able to override the inhibition of luteinization by indomethacin (150 μg/ml). The prostaglandin analogue 7-oxa-13-prostynoic acid (100 μg/ml) failed to prevent luteinization in response to either 5 μg/ml LH or 1 μg/ml PGE₂. Results with PGE₂ and with indomethacin suggest a role for prostaglandins in the luteinizing action of LH.We have reported previously that in vitro exposure of diestrous rat follicles to luteinizing hormone (LH) will result in transformation of the follicles to corpora lutea following transplantation under the kidney capsules of hypophysectomized rats. Dibutyryl cyclic AMP (DBC) mimics this effect of LH, and transplants produce progesterone in measurable amounts after both LH and DBC exposure when prolactin is administered in vivo to recipients.Kuehl et al. have suggested that prostaglandins may act as obligatory intermediates in the effect of LH on the ovary, acting between LH and adenylate cyclase. Preliminary results indicated that prostaglandin E₂ (PGE₂) could induce luteinization in our system. The extent of prostaglandin involvement in luteinization was further investigated in this work, using two reported antagonists of prostaglandin action, indomethacin and 7-oxa-13-prostynoic acid. Indomethacin has been found to inhibit synthesis of prostaglandins E₂ and F_2α; 7-oxa-13-prostynoic acid, which acts as a competitive antagonist of prostaglandins, prevented the effect of LH and prostaglandins E₁ and E₂ on cyclic AMP production in mouse ovaries.     

Isolation and characterization of red-pigment-concentrating hormone (RPCH) from six crustacean species

Summary Red-pigment-concentrating hormone (RPCH) has been isolated from nerve tissue of six decapod crustaccan species. The primary structure of three of the six hormones, i.e., those ofCancer magister, Carcinus maenas andOrconectes limosus, was determined by manual microsequencing as: pELNFSPGW-NH₂. This sequence is identical to that of RPCH fromPandalus borealis, the only previously known sequence of a crustacean RPCH. The other three hormones fromLiocarcinus puber, Nephrops norvegicus, andPacifastacus leniusculus could not be characterized completely. However, amino acid compositions, the presence of N-terminal pGlu, and the blocked N-terminal ends are in accordance with the primary structure established for the other three RPCHs. We suggest that all six peptides have the same amino acid sequence. These results indicate that RPCH, which is likely to be related to the peptides of the AKH family in insects, is highly conserved among crustacean species. This is in remarkable contrast to the high degree of molecular evolution exemplified by the many different AKH-like peptides among insect species.Abbreviations AKH adipokinetic hormone - Aufs absorption units full scale - BSA bovine serum albumin - ECH erythrophore concentrating hormone (=RPCH) - EDTA ethylenediamine-tetra-acetic acid - HOAc acetic acid - HPLC high pressure liquid chromatography - O.D. optical density - PDH pigment dispersing hormone - PGAP pyroglutamate aminopeptidase - RPCH red-pigment-concentrating hormone (=ECH) - SOG suboesophageal ganglion - TFA trifluoroacetic acid     

Desensitization of testicular ornithine decarboxylase to gonadotropin releasing hormone and gonadotropic hormones

Prior exposure of the testis to gonadotropin releasing hormone, luteinizing hormone or follicle stimulating hormone caused the testis refractory to these hormones in terms of ornithine decarboxylase activity at 24 h. Luteinizing hormone caused desensitization in the Leydig cells while the levels of ornithine decarboxylase in the seminiferous tubules were unaltered. In gonadotropin releasing hormone desensitized testis all the other treated compounds namely, luteinizing hormone, follicle stimulating hormone, prostaglandin F2 alpha, norepinephrine and cyclic AMP caused stimulation of ornithine decarboxylase activity. The testis desensitized with LH responded to cyclic AMP and norepinephrine whereas prostaglandin E2 or gonadotropin releasing hormone caused less stimulation of ornithine decarboxylase activity. These results indicate that testicular desensitization to gonadotropin releasing hormone and luteinizing hormone is not due to a post cyclic AMP block.